Tryptophan Induced Eosinophilia-Myalgia Syndrome: Clinical and Microscopic Findings

Martin RW Duffy J Engel AG , et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Ann Intern Med 1990; 113: 124–34

Smith BB Duck PJ . Peripheral neuropathy in the eosinophilia myalgia syndrome associated with L-tryptophan ingestion. Neurology 1990; 40: 1035–40

Mayeno AN Lin F Foote CS , et al. Characterization of “peak E” a novel amino acid associated with eosinophilia-myalgia syndrome. Science 1990; 250: 1797–8

Kaufman LD Seidman RJ Phillips ME Gruber BL . Cutaneous manifestations of the L-tryptophan-associated eosinophilia-myalgia syndrome: A spectrum of sclerodermatous skin disease. J Am Acad Dermatol 1990; 23: 1063–9

Dublin DB Kwan TH Morse MO Case DC . Cutaneous mucinosis in a patient with eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Arch Dermatol 1990; 126: 1517–18

Farmer KL Herbert AA Rapini RP Jordan RE : Dermal mucinosis in the eosinophilia-myalgia syndrome. Arch Dermatol 1990; 126: 1518–20

Sappino A-P Masouye I Saurat J-H Gabbiani G . Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990; 137: 585–91

Toxic Epidemic Syndrome Study Group: Toxic epidemic syndrome, Spain, 1981. Lancet 1982; ii: 697–702